Researchers conducted a network meta-analysis to compare several medications for people with moderate to severe ulcerative colitis. The study looked at drugs including Upadacitinib, Ustekinumab, Risankizumab, Guselkumab, and Mirikizumab. They specifically looked at how well these drugs worked to achieve clinical remission and endoscopic improvement during both the initial treatment and long-term maintenance phases.
During the initial treatment phase, Upadacitinib, Ustekinumab, and Risankizumab were all found to be among the most favorable options. For long-term maintenance, Upadacitinib at a 30 mg dose showed the highest ranking for effectiveness. Additionally, IL-23 antagonists like Guselkumab and Mirikinumab, along with low-dose Upadacitinib, showed a very favorable balance between being effective and being well-tolerated by patients.
It is important to note that this study is a network meta-analysis, which means it compares several treatments indirectly rather than through direct head-to-head trials. Because there are few direct comparisons between these specific drugs, the results should be viewed as a guide for doctors. Patients should talk to their healthcare provider to decide which treatment fits their specific medical history and needs.
